Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04939428 · ClinicalTrials.gov registry record · Phase 3
Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,441
- Enrollment target
NCT04939428: Completed Phase 3 study, sponsored by Merck Sharp & Dohme.
NCT04939428 is a Phase 3 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 2,441 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (216% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04939428, a Phase 3 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,441 participants
- Enrollment target
Study Summary
The purpose of the study is to assess if the study medication (molnupiravir, MK-4482) will prevent symptomatic coronavirus disease 2019 (COVID-19) in adults who live with someone with confirmed COVID-19 infection. This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study; half of the study participants will receive molnupiravir twice daily by mouth and the other half will receive a placebo. The primary objectives of the study are to determine if molnupiravir prevents symptomatic COVID-19 disease and to evaluate its safety and tolerability. All participants who develop COVID-19 during the study are still eligible for any COVID-19 treatment recommended by their doctor.
Primary Outcome
Percentage of participants who had undetectable SARS-CoV-2 in baseline NP swabs and developed COVID-19 (laboratory-confirmed SARS-CoV-2 infection with symptoms) through Day 14 were reported.
Interventions
- DRUG Placebo
- DRUG Molnupiravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,441 participants |
| Start Date | 2021-08-11 |
| Est. Completion | 2022-11-16 |
| Phase | Phase 3 |
What the finished NCT04939428 record still lists
NCT04939428 is an interventional study that assigns participants to a tested intervention. Its 2,441 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (216% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04939428 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04939428 about?
NCT04939428 is a clinical study titled "Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)". The purpose of the study is to assess if the study medication (molnupiravir, MK-4482) will prevent symptomatic coronavirus disease 2019 (COVID-19) in adults who live with someone with confirmed COVID-19 infection. This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study; ha...
What is the current status of trial NCT04939428?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,441 participants. The study started on 2021-08-11. Estimated completion is 2022-11-16.
What interventions are being tested in trial NCT04939428?
The interventions under investigation include: Placebo (DRUG), Molnupiravir (DRUG).
Who is sponsoring clinical trial NCT04939428?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04939428's enrollment target sits among peer trials
2,441 88th of 2000 higher than 1,913 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06128304 · 2,436 participants · NA
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
- NCT06898593 · 2,448 participants · NA
Enhancing Engagement by Integrating Goals and Concerns That Matter to Patients
- NCT06676904 · 2,433 participants · NA
Neonatal Platelet Transfusion Threshold Trial
- NCT05345951 · 2,425 participants · NA
Project e-PBI+ - Parent Intervention to Reduce College Student Drinking and Cannabis Use
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI